# HERSTON HEALTH PRECINCT SYMPOSIUM 2021

6 - 10 September 2021 Education Centre RBWH

## CLIN-0035

## Integrated versus non-integrated peripheral intravenous catheter in hospitalised adults (OPTIMUM) study: A randomized controlled trial

Claire Rickard<sup>1-5</sup>, Emily Larsen<sup>1,2,4</sup>, Rachel Walker<sup>4,5</sup>, Gabor Mihala<sup>1,4</sup>, Joshua Byrnes<sup>1,4</sup>, Masnoon Saiyed<sup>1,4</sup>, Julie Finucane<sup>1,4,5</sup>, Nicole Marsh<sup>1-4</sup>

1. Alliance for Vascular Access Teaching and Research 2. Metro North Hospital and Health Service 3. University of Queensland 4. Griffith University 5. Metro South Hospital and Health Service

#### **PURPOSE**

To compare **integrated** peripheral intravenous catheters (PIVCs) and **non-integrated PIVCs** for the prevention of **device failure**.


Healthcare Innovations

How practice has

changed

#### **METHOD**

Medical/surgical adult patients requiring intravenous therapy for >24 hours were enrolled between July 2017 and December 2019. Patients were randomised to either **integrated** (*n*=881) or **non-integrated PIVC** (*n*=878). One PIVC was studied per patient.



The primary outcome was **device failure**, a composite of occlusion, infiltration, phlebitis, dislodgement, and local/bloodstream infection. Secondary outcomes included failure type, first-time insertion success, tip colonisation, insertion pain, dwell time, mortality, hospital costs, and health-related quality of life. Clinician and patient satisfaction were measured in a subset.





KEY FINDINGS	Integrated PIVC	Non-integrated PIVC
Device failure <sup>ns</sup>	33%	35%
Failure/1,000 device-days*	124	145
Dislodgement/leakage*	39	53
Hospital costs <sup>ns</sup>	\$40 per patient	\$38 per patient

\* p < .05; <sup>ns</sup> no significant difference

QUI

#### RESULTS

pathology

queensland

Among **1,759** randomised patients (mean [SD] age, 60 [17] years, 60% male, 70% multiple comorbidities), 1,710 (97%) received a PIVC and were included in the modified intention-to-treat analysis.

THE UNIVERSITY

OF QUEENSLAND

AUSTRALIA

CREATE CHANG





Device failure was less common in non-integrated PIVCs (absolute risk difference -2.8% (95% Cl -7.3% to -1.7%). However, integrated PIVCs had significantly longer dwell, and less dislodgement/leaking (both p<0.05). The multivariate model found **significantly reduced PIVC failure for integrated PIVCs** (HR 0.82, 95% Cl 0.69 to 0.96) adjusted for gender, baseline infection, gauge, department, and insertion site. There was **no significant** difference in direct hospital costs (\$2.02 (95% Cl \$-8.86 to \$4.81).

### CONCLUSIONS

Integrated PIVCs resulted in a relative 18% less PIVC failure than non-integrated PIVCs in hospitalised adult patients. This could reduce burden of treatment interruptions and re-insertion procedures.



HERSTON

HEALTH PRECINCT



